If You Invested in Abbott Laboratories (ABT)

Abbott Laboratories (NYSE: ABT) is a global healthcare company whose businesses span diagnostics, medical devices, nutritionals and branded generic medicines. According to the company, its portfolio of technologies is designed to help people live more fully at all stages of life, and its colleagues serve people in more than 160 countries. Abbott’s common shares trade on the New York Stock Exchange under the symbol ABT.

Abbott is classified in pharmaceutical preparation manufacturing within the broader manufacturing sector, but its activities extend across multiple areas of healthcare. The company manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Its products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Available information indicates that Abbott derives a significant portion of its sales outside the United States.

Diagnostics and Cancer Screening

Diagnostics is one of Abbott’s core businesses. The company highlights leading businesses and products in diagnostics, and has announced plans to expand further in this area through an Agreement and Plan of Merger with Exact Sciences Corporation. Under this agreement, a wholly owned Abbott subsidiary will merge with Exact Sciences, with Exact Sciences surviving as a direct, wholly owned subsidiary of Abbott, subject to customary closing conditions. Exact Sciences focuses on early detection of cancer and supporting personalized treatments through cancer screening, precision oncology and genetic testing, including stool-based and liquid biopsy tests, molecular residual disease monitoring and treatment guidance.

Through this planned acquisition, Abbott expects to add product lines that include noninvasive colorectal cancer screening tests, tests that inform treatment decisions in breast cancer, molecular residual disease tests to help assess risk of recurrence, and multi-cancer early detection blood tests. The companies have stated that combining their capabilities is intended to accelerate innovation and expand access to cancer diagnostics that can help detect cancer earlier and guide treatment and monitoring.

Medical Devices and Cardiovascular Care

Abbott reports a broad medical devices business, including technologies for cardiovascular and electrophysiology care. The company has announced that the U.S. Food and Drug Administration (FDA) approved its Volt PFA System to treat patients with atrial fibrillation (AFib). Pulsed field ablation (PFA) is described as a minimally invasive procedure that uses high-energy electrical pulses in targeted areas of the heart to treat irregular heart rhythms. Abbott states that the Volt PFA System is an all-in-one product that allows physicians to map, pace and ablate with the same catheter, and that it is designed to integrate with the company’s EnSite X EP System to provide 3D cardiac mapping and support efficient procedures.

Abbott also develops devices for structural heart and pediatric cardiology. The company has received FDA clearance and CE Mark for its Amplatzer Piccolo Delivery System, used with the Amplatzer Piccolo Occluder to treat premature babies with a patent ductus arteriosus (PDA), a potentially life-threatening opening in the heart. The Amplatzer Piccolo Occluder is described as a minimally invasive, transcatheter treatment approved to close a PDA in premature infants. Abbott notes that this device is smaller than a pea and is intended for some of the tiniest patients. The company’s pediatric heart portfolio also includes the Masters HP 15mm mechanical heart valve and the HeartMate 3 heart pump, which is approved for pediatric patients.

Diabetes Care, Biowearables and Digital Health

Diabetes care and metabolic health are important areas for Abbott. The company manufactures continuous glucose monitoring (CGM) systems under the FreeStyle Libre brand, which it describes as a world-leading portfolio used by millions of people across many countries. These systems allow users to see glucose numbers in real time and understand how food, activity or insulin impact glucose levels.

Building on this technology, Abbott has introduced digital tools that combine CGM data with software and generative artificial intelligence. The Libre Assist feature, available within the Libre app, is designed to help people living with diabetes in the United States better understand how foods may affect their glucose levels. According to Abbott, Libre Assist uses generative AI to predict how a food choice may affect glucose, offers personalized meal guidance based on user inputs, and then confirms the impact using data from Libre CGM sensors. The feature provides color-coded ratings of potential glucose impact and practical tips to help lower that impact, and it is available at no additional cost within the app.

Abbott has also launched Lingo, an over-the-counter continuous glucose monitor and app aimed at adults who are not on insulin but want to understand how lifestyle factors affect their glucose. Lingo is available in the U.S. and the U.K. and is intended for users 18 years and older. The system provides real-time glucose data and uses a metric called Lingo Count to quantify the impact of glucose spikes. Abbott has reported real-world data suggesting that reducing Lingo Count over time is associated with improvements in glucose measures among users with elevated levels.

Nutritionals and Muscle Health

Nutrition is another major business for Abbott. The company describes itself as a global leader in science-based nutrition and offers adult and pediatric nutritional products. Within this portfolio, Abbott has expanded the Ensure Max Protein line with new shakes designed to support muscle health and nutrition goals. The company notes that aging, nutrition and lifestyle affect muscles, and that muscle mass can decline with age.

Ensure Max Protein 42g is described as a shake formulated for physically active adults, with a high level of protein, vitamins, minerals and electrolytes to support muscle function. Ensure Max Protein 2 in 1 Muscle Support is intended for older adults who need help maintaining muscle as they age, and includes protein along with CaHMB (beta-hydroxy-beta-methylbutyrate), which Abbott cites as an ingredient that can help slow the breakdown of muscle. The company references research indicating that combining high-quality protein with HMB can support muscle health when used alongside resistance training.

Branded Generic Medicines and Global Reach

Abbott identifies branded generic medicines as one of its primary business areas. While specific products are not detailed in the provided materials, the company consistently refers to branded generic medicines as a core part of its portfolio, alongside diagnostics, medical devices and nutritionals. Abbott states that it serves people in more than 160 countries, indicating a broad geographic footprint for its healthcare products and technologies.

Community Programs and Partnerships

Beyond its product lines, Abbott engages in programs and partnerships related to public health and patient support. The company created the HeartMates community to provide a space for people impacted by heart health challenges, including patients, families, caregivers and medical support teams. HeartMates participants take part in in-person and virtual events where they can share experiences and support one another.

Abbott has also partnered with the Big Ten Conference on the "We Give Blood" competition, a nationwide blood drive initiative. The program encourages students, alumni and fans to donate blood, with donations contributing to strengthening the blood supply. Abbott reports that the initiative has generated tens of thousands of donations and that survey data indicates a high likelihood of repeat donations among participants.

Corporate Governance and Exchange Listing

Abbott Laboratories is incorporated in Illinois and files reports with the U.S. Securities and Exchange Commission. Its common shares, without par value, are registered under Section 12(b) of the Securities Exchange Act of 1934 and are listed on the New York Stock Exchange. Recent SEC filings show that Abbott’s board of directors has been expanded and that the company continues to manage corporate governance matters such as amendments to its by-laws and administration of employee benefit plans.

Dividend Track Record

Abbott highlights a long history of paying and increasing dividends. The company has announced that it has increased its quarterly common dividend for many consecutive years and has paid hundreds of consecutive quarterly dividends since the 1920s. Abbott is identified as a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.